Tuesday, March 1, 2022

Financial News Conference on the Full Year 2021 Results

Bayer: Dynamic growth – progress in innovation

  • Group sales increase by 8.9 percent (Fx & portfolio adj.) to 44.081 billion euros

  • EBITDA before special items declines by 2.5 percent to 11.179 billion euros – inflation-related increase in costs and negative currency effects largely offset

  • Crop Science grows sales by double-digit percentage (Fx & portfolio adj.) and increases earnings

  • Pharmaceuticals posts higher sales – earnings decline slightly year on year due to extensive forward-looking investment

  • Consumer Health delivers excellent performance

  • Core earnings per share rise by 1.9 percent to 6.51 euros

  • Net income: 1 billion euros

  • Free cash flow (1.415 billion euros) and net financial debt (33.137 billion euros) much better than expected

  • Proposed dividend: 2.00 euros per share

  • Successful product launches and progress with platform technologies

  • Good progress with the implementation of long-term sustainability goals: direct and indirect CO2 emissions down by 11.5 percent

  • Outlook for 2022: Significant increase in sales, earnings and free cash flow

MORE

Recording (partly dubbed into English):

Video: Webcast

Audio:

 

(MP3 download, 78.01 MB)


Statements in written form

 

Recording (partly dubbed into English):

Video: Webcast (please use the jump marks in the video stream to jump the the desired position)

Audio:

(MP3 download, 38.68 MB)

Recording (partly dubbed into English):

Video: Webcast (please use the jump marks in the video stream to jump the the desired position)

Audio:

(MP3 download, 37.05 MB)